KIT and severe combined immunodeficiency: Similarly, a mAb against CD117 (or c-Kit), necessary for survival, proliferation, and differentiation of hematopoietic stem cells and early progenitors, has demonstrated good preclinical results in animal models and is being tested in patients with SCID (ClinicalTrials.gov Identifier: NCT02963064)193–195.